In a patient with chronic myelomonocytic leukemia (CMML) who has a pericardial effusion and a pericardial biopsy showing blast cells without a solid mass, what is the appropriate term for this finding and how should it be managed?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Pericardial Involvement in CMML: Terminology and Management

When blast cells infiltrate the pericardium without forming a solid mass in a CMML patient with pericardial effusion, this represents extramedullary disease (EMD) or pericardial involvement by CMML, and should be managed with systemic chemotherapy as the primary approach.

Terminology and Classification

The finding of blast cells in pericardial tissue without a discrete tumor mass represents extramedullary disease (EMD) or pericardial involvement by CMML 1, 2. This differs from a myeloid sarcoma (also called granulocytic sarcoma or chloroma), which presents as a solid tumor mass of myeloid blasts 3.

  • Pericardial involvement indicates infiltration of CMML cells into the pericardium, typically manifesting as pericardial effusion containing monocytes and blast cells
  • This is a form of non-hepatosplenic EMD, which occurs in 10-15% of CMML patients and carries adverse prognostic implications 2
  • The presence of EMD is associated with proliferative CMML phenotypes, higher blast counts, and enrichment of RAS/MAPK pathway mutations 2

Diagnostic Confirmation

The diagnosis requires:

  • Tissue confirmation from pericardial biopsy showing blast cells and monocytic infiltration
  • Immunophenotyping with CD68, CD163, and lysozyme to confirm monocytic lineage 2
  • Cytology of pericardial fluid typically shows predominance of monocytes 4, 5, 6
  • Molecular profiling to establish clonality and identify the same mutations present in bone marrow 2

Prognostic Implications

This finding indicates high-risk disease with poor prognosis:

  • EMD is associated with shorter overall survival and increased risk of AML transformation 2
  • Pericardial involvement can be life-threatening, causing cardiac tamponade requiring urgent intervention 3, 7, 4
  • EMD typically occurs during uncontrolled leukocytosis and reflects aggressive disease biology 4

Management Strategy

Immediate Management

  1. Address cardiac tamponade if present: Pericardiocentesis or pericardial window for symptomatic relief 3, 7
  2. Initiate systemic therapy promptly - local measures alone are insufficient

Systemic Treatment Approach

Primary systemic therapy is essential because pericardial involvement represents disseminated disease 1, 2:

For CMML-2 with high blast count (≥10% bone marrow blasts):

  • Hypomethylating agents (HMAs) such as azacitidine are the backbone of therapy 1, 2
  • Intensive chemotherapy may be considered for patients with CMML-2 and high blast burden, particularly if transformation to AML is occurring 1
  • Etoposide has shown efficacy in historical case reports of CMML with pericardial effusion, with rapid response 4, 5, 6

For proliferative CMML with lower blast count:

  • Cytoreductive therapy with hydroxyurea to control leukocytosis 1
  • This is particularly relevant since pericardial effusions in CMML typically develop during uncontrolled leukocytosis 4

Definitive Treatment

Allogeneic hematopoietic cell transplantation (allo-HCT) should be strongly considered 8, 1, 2:

  • EMD identifies patients with adverse disease biology who are at high risk for progression
  • The 2024 EBMT guidelines recommend that once a patient is identified as a transplant candidate, upfront transplantation should be pursued to maximize chances of reaching allo-HCT 8
  • Allo-HCT remains the only potentially curative option for CMML 8, 1
  • Early consideration of transplant is particularly important in EMD cases given the poor prognosis 2

Treatment Sequence

  1. Stabilize hemodynamics with pericardial drainage if tamponade present
  2. Initiate systemic therapy immediately: HMA (azacitidine) for CMML-2 with high blasts, or cytoreductive therapy for proliferative disease
  3. Evaluate for allo-HCT eligibility urgently, as EMD indicates high-risk disease
  4. Proceed to transplant in eligible patients without delay once disease control is achieved

Critical Pitfalls to Avoid

  • Do not rely on local therapy alone (pericardiocentesis, pericardial window, or radiation) - systemic disease requires systemic treatment 2
  • Do not delay transplant evaluation - EMD indicates aggressive biology requiring definitive therapy 8, 2
  • Do not mistake this for infection or inflammatory pericarditis - tissue diagnosis with immunophenotyping is essential 2
  • Monitor closely after initial response - pericardial effusions may persist despite peripheral blood response, requiring continued systemic therapy 5

Related Questions

What is the prognosis for an elderly male diagnosed with chronic myelomonocytic leukemia who presents with marked monocytosis and hyperuricemia?
What are the differences between chronic myelomonocytic leukemia (CMML) and myelodysplastic syndrome (MDS)?
What are the contraindications for neuraxial anesthesia and central nervous system surgery in chronic myelomonocytic leukemia, including platelet count, coagulation parameters, neutrophil count, and risk of leukemic infiltration?
Can an adult with chronic myeloid leukemia have an extramedullary mass persisting for 18 months without disease progression?
Given a patient with CMML (MDS/MPN overlap) presenting with extreme thrombocytosis (>1.5 ×10⁶/µL), MPL mutation, recent transient ischemic attack, refractory to hydroxyurea and maximal-dose anagrelide, grade IV neutropenia, not a transplant candidate and ineligible for hypomethylating agents, what therapeutic options are appropriate?
What is the current standard for surgical management of inguinal hernia in children: open high‑ligature repair versus laparoscopic repair?
What is the appropriate treatment for hypophosphatemia?
How does squamous cell carcinoma of the lung respond to oncologic therapy?
What is the semiological term for the pinch and grasp function of the thumb (first digit) of the hand?
Which obstetric conditions warrant a gluten‑free diet in pregnant patients?
What is the recommended dosing of tadalafil for erectile dysfunction and pulmonary arterial hypertension, and what are its contraindications and precautions?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.